Drug major GlaxoSmithKline (GSK) has unethically tested a breast cancer drug on poor patients in India for approval for new drugs in the Europe Union, said a study. According to an investigation by Mumbai-based Centre for Studies in Ethics and Rights, the firm tested lapatinib on patients flouting Indian Council of Medical Research's (ICMR) ethical guidelines.This trial required seriously ill patients who had not received treatment for their condition.
RTI Health Solutions (RTI-HS), a business unit of RTI International, partnered with the U.S. Food and Drug Administration to conduct a study on patients' preferences which contributed to the Agency's regulatory decision to approve t... Read Post
Two people working as brokers for a Hyderabad-based pharmaceutical company were Friday arrested in Andhra Pradesh's Guntur district for engaging poor women for unauthorised drug trials, police said. Kommu Karunamma and Shaikh Jameel... Read Post